Pediatric pulmonology · Genetic Pulmonary Surfactant Dysfunction

The Daily Journey: Respiratory Support, Nutrition, and Medical Management

At a Glance

Babies with genetic surfactant dysfunction need individualized supportive care because current treatments do not correct the underlying gene change. Respiratory support, nutrition planning, careful medication monitoring, home safety, and coordinated specialist care are central.

Managing genetic surfactant dysfunction is a marathon, not a sprint. Because these conditions are caused by an alteration in the DNA, there is currently no cure that fixes the underlying defect ^[1]. Instead, medical management focuses on supportive care: providing the lungs, heart, and body with everything they need to grow and function ^[2].

The Respiratory Support Framework

Every baby’s needs are unique. Your team will tailor a combination of supports to ensure your baby gets enough oxygen without overworking their breathing muscles ^[3].

Supplemental Oxygen: Many babies require extra oxygen delivered via a small tube in the nose ^[4]. Oxygen targets are highly individualized depending on age, sleep state, and whether pulmonary hypertension is present. Your doctor will prescribe a specific target range. Never adjust oxygen flow without explicit, written instructions from your clinical team, as excessive oxygen can also be harmful.
Non-Invasive Ventilation (CPAP/BiPAP): These machines provide continuous air pressure to help keep the fragile air sacs open, reducing the “work” of breathing ^[3].
Invasive Ventilation: If a baby’s lungs are very stiff, a breathing tube (connected to a ventilator) may be necessary to do the work for them ^[4].

Nutrition: The “Treatable Trait”

In surfactant disorders, nutrition is an active part of treatment ^[2]. Babies with lung disease often have significantly increased energy needs because breathing takes an enormous amount of calories ^[5].

Growth Monitoring: “Falling off the curve” (poor growth) is a sign that the baby needs more energy ^[6].
Feeding Tubes: If a baby is too tired to feed by mouth, or if they are at risk of aspiration (inhaling milk or saliva into the lungs), a feeding tube may be used ^[7]. This may be a nasogastric (NG) tube or a gastrostomy (G-tube) placed directly into the stomach. Note: A G-tube supports nutrition but does not eliminate the risk of aspirating refluxed stomach contents or oral secretions. A feeding/swallowing specialist will help create an individualized plan ^[8]^[9].

Medications: An Uncertain Path

You may hear about “empiric” or off-label medications. The evidence for these drugs in surfactant dysfunction is generally weak, based on small observational studies, and they are not routine cures ^[10]^[11]. They should only be used under a specialist protocol.

Medication	Intended Role	Important Considerations
Corticosteroids	Used to reduce lung inflammation ^[11].	Rarely halts disease progression in ABCA3 or SFTPB ^[10]. Carries risks for infection and negative impacts on growth ^[12].
Hydroxychloroquine	Sometimes used in an attempt to manage cellular stress/inflammation ^[13].	Benefit is highly uncertain. Requires strict specialist monitoring, including regular ophthalmology (eye) exams ^[11]^[14].
Azithromycin	Used for anti-inflammatory properties ^[13].	Requires monitoring for heart rhythm (ECG/QT) risks ^[14].

Home Safety and Preparedness

If your baby goes home on medical equipment, you will need specific training. Your home care plan should include:

Equipment Safety: Fire and smoking precautions for home oxygen.
Emergency Backups: Backup oxygen tanks and power supplies for monitors/ventilators.
Infection Prevention: A strict plan for routine immunizations and seasonal respiratory-virus prevention.
Escalation Plan: Written instructions on who to call after hours for equipment failure, fever, or breathing changes.

The Gold Standard: Multidisciplinary Care

The most effective way to manage these rare conditions is through a multidisciplinary care team at a specialized center ^[2]. This includes pulmonologists, geneticists, dietitians, cardiologists, and social workers ^[15]^[16]. Palliative care specialists are also frequently involved—not as a sign of giving up, but to expertly manage symptoms and support the family’s quality of life alongside active medical treatments ^[1].

Common questions in this guide

What kinds of breathing support might my baby need?

Support is individualized. A baby may receive oxygen through a nasal tube, CPAP or BiPAP to help keep the air sacs open, or a ventilator through a breathing tube if the lungs cannot do enough work. Do not change oxygen flow or targets unless the specialist team gives written instructions.

How are my baby's oxygen targets decided?

The care team sets a specific oxygen saturation range based on age, whether the baby is awake or asleep, and whether pulmonary hypertension is present. Targets are individualized, and oxygen flow should never be changed without explicit written instructions.

How can nutrition help a baby with surfactant dysfunction?

Breathing problems can greatly increase calorie needs, so growth and feeding are part of medical care. If a baby tires during feeds or may inhale milk or saliva, an NG or G-tube can provide nutrition. A G-tube supports feeding but does not completely prevent aspiration from reflux or oral secretions.

Are medicines such as steroids or hydroxychloroquine a cure?

No medication listed for genetic surfactant dysfunction is a proven routine cure. These medicines may be tried to reduce inflammation or cellular stress, but evidence is limited and they require specialist oversight; hydroxychloroquine calls for regular eye exams, and azithromycin may require heart-rhythm checks.

What should our family know before bringing respiratory equipment home?

Caregivers need hands-on training for oxygen, monitors, ventilators, or feeding tubes. The home plan should address fire and smoking safety, backup oxygen and power, infection prevention, and clear after-hours instructions for equipment problems, fever, or breathing changes.

Which specialists usually help manage this condition?

Care is often coordinated through a specialized center and may include a pulmonologist, geneticist, dietitian, cardiologist, and social worker. Palliative care can also be involved during active treatment to help control symptoms and support the family's quality of life; it does not mean that treatment is being stopped.

Get notified when new evidence is published on Chronic respiratory distress with surfactant metabolism deficiency.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References (16)

1
Genetic Disorders of Surfactant Metabolism.
Nevel RJ, Brennan SK, Wambach JA
NeoReviews 2025; (26(5)):e328-e338 doi:10.1542/neo.26-5-014.
PMID: 40306683
2
Treatable Traits in Pediatric Interstitial Lung Diseases: Bridging the Gap to Tailored Therapeutics.
Parisi GF, Papale M, Pecora G, et al.
Journal of clinical medicine 2025; (14(22)) doi:10.3390/jcm14228190.
PMID: 41303225
3
Home continuous positive airway pressure therapy in infants: a single-center experience.
Joshi SS, Sivapalan D, Leclerc MJ, Kapur N
Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine 2023; (19(3)):473-477 doi:10.5664/jcsm.10366.
PMID: 36458731
4
Respiratory Outcomes in Children With Neonatal Respiratory Distress Syndrome and Monoallelic ABCA3 Variants.
Ramírez VO, Wambach JA, Nevel RJ, et al.
Pediatric pulmonology 2026; (61(6)):e71695 doi:10.1002/ppul.71695.
PMID: 42295024
5
Do we neglect nutrition in childhood interstitial lung disease?
Emiralioglu N, Kiper N
European journal of clinical nutrition 2024; (78(12)):1023-1024 doi:10.1038/s41430-024-01485-x.
PMID: 39107487
6
Clinical and genetic spectrum of interstitial lung disease in Chinese children associated with surfactant protein C mutations.
Hong D, Dai D, Liu J, et al.
Italian journal of pediatrics 2019; (45(1)):117 doi:10.1186/s13052-019-0710-2.
PMID: 31462320
7
Epidemiology of childhood interstitial lung disease in France: the RespiRare cohort.
Fletcher C, Hadchouel A, Thumerelle C, et al.
Thorax 2024; (79(9)):842-852 doi:10.1136/thorax-2023-221325.
PMID: 38964860
8
Home Enteral Tube Feeding in Children and Young People: A Review of Current Literature on Optimum Frequency and Mode of Dietetic Assessment and Monitoring in the Community Setting.
Baker H, Durnan S, Pugh P
Journal of human nutrition and dietetics : the official journal of the British Dietetic Association 2025; (38(2)):e70044 doi:10.1111/jhn.70044.
PMID: 40159683
9
Gold Standard Home Nasogastric Tube Feeding for Infants and Children.
, Breik L, Chaffey E, et al.
Journal of paediatrics and child health 2025; (61(7)):1006-1013 doi:10.1111/jpc.70052.
PMID: 40269492
10
Inherited pulmonary surfactant metabolism disorders in Argentina: Differences between patients with SFTPC and ABCA3 variants.
Balinotti JE, Mallie C, Maffey A, et al.
Pediatric pulmonology 2023; (58(2)):540-549 doi:10.1002/ppul.26225.
PMID: 36324278
11
A comparative analysis of clinical phenotypes and outcomes in childhood interstitial lung disease due to surfactant dysfunction disorders: focusing on mutations in SFTPC, ABCA3, and NKX2-1 genes.
Tang X, Zhao S, Shen Y, et al.
Italian journal of pediatrics 2025; (51(1)):265 doi:10.1186/s13052-025-02110-8.
PMID: 40866983
12
Surfactant proteins gene variants in premature newborn infants with severe respiratory distress syndrome.
Somaschini M, Presi S, Ferrari M, et al.
Journal of perinatology : official journal of the California Perinatal Association 2018; (38(4)):337-344 doi:10.1038/s41372-017-0018-2.
PMID: 29255193
13
[Surfactant protein C dysfunction in pediatric patients: Clinical Case].
Nuñez-Paucar H, Valera-Moreno C, Atamari-Anahui N, et al.
Andes pediatrica : revista Chilena de pediatria 2022; (93(5)):733-740 doi:10.32641/andespediatr.v93i5.3873.
PMID: 37906894
14
Hydroxychloroquine, a successful treatment for lung disease in ABCA3 deficiency gene mutation: a case report.
Shaaban W, Hammoud M, Abdulraheem A, et al.
Journal of medical case reports 2021; (15(1)):54 doi:10.1186/s13256-020-02604-5.
PMID: 33526094
15
The significance of multidisciplinary team meetings in diagnosing and managing childhood interstitial lung disease within the RespiRare network.
Cassibba J, Epaud R, Berteloot L, et al.
Pediatric pulmonology 2024; (59(2)):417-425 doi:10.1002/ppul.26765.
PMID: 37991126
16
An update to the classification, evaluation, and management of childhood interstitial lung disease in infancy: an official American Thoracic Society Clinical Practice Guideline.
McGraw MD, DeBoer E, Weinman JP, et al.
American journal of respiratory and critical care medicine 2026; (212(10)):2308-2337 doi:10.1093/ajrccm/aamag375.
PMID: 42496593

This page is for informational purposes only and does not constitute medical advice. Your baby's pulmonary and genetics team should set oxygen, feeding, medication, and home-equipment plans for your child's specific needs.